Physician profile
Steven Bialick
NPI 1750745063
$11,144.97
in general payments reported to CMS, 2019-2025
37 companies · $9,111 in 2025
The $9,111 reported for 2025 was more than what 80% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $231 · 2023: $343 · 2024: $1,057 · 2025: $9,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,828 · Food and Beverage: $2,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,827.50 |
| Food and Beverage | $2,683.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $7,464.35 | 2024-2025 | Ogsiveo |
| Daiichi Sankyo INC. | $899.27 | 2024-2025 | Turalio, Enhertu, Datroway |
| Janssen Biotech, INC. | $383.53 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Aadi Bioscience, INC. | $311.11 | 2024-2025 | Fyarro |
| Intera Oncology, INC | $182.36 | 2024 | Intera |
| Celgene Corporation | $174.68 | 2021-2023 | Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.60 | 2021-2025 | |
| Seagen INC. | $132.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $131.57 | 2024-2025 | |
| Taiho Oncology, INC. | $122.08 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.91 | 2024-2025 | Opdivo, Krazati |
| Foundation Medicine, INC. | $110.42 | 2022 | |
| Adaptive Biotechnologies Corporation | $90.02 | 2023 | Clonoseq |
| Eisai INC. | $88.26 | 2023-2025 | |
| Array Biopharma INC | $81.19 | 2024-2025 | Braftovi, Tukysa, Mektovi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62.09 | 2024-2025 | Jemperli, Zejula |
| Caris Mpi, INC. | $50.05 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $44.13 | 2024-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $43.81 | 2024-2025 | Keytruda |
| Incyte Corporation | $43.15 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $43.05 | 2025 | Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $42.84 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $40.33 | 2024 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $40.28 | 2024 | Venclexta, Tecentriq |
| Beone Medicines USA, INC. | $39.49 | 2025 | Tevimbra |
| Beigene USA, INC. | $37.28 | 2024-2025 | Tevimbra |
| Immunocore Limited | $26.95 | 2024 | Kimmtrak |
| Servier Pharmaceuticals LLC | $24.94 | 2025 | |
| Sun Pharmaceutical Industries INC. | $24.80 | 2025 | |
| Genentech, INC. | $24.75 | 2023 | Polivy |
| Deciphera Pharmaceuticals INC. | $23.54 | 2024 | Tgct, Qinlock |
| Gilead Sciences, INC. | $22.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.06 | 2025 | Ninlaro |
| Mirati Therapeutics, INC. | $18.97 | 2024 | Krazati |
| Tactile Systems Technology INC | $18.77 | 2024 | Flexitouch Plus, Entre Plus |
| Genzyme Corporation | $14.30 | 2024 | |
| Coherus Oncology, INC. | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bialick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.